Aehr Test Systems is engaged in test systems for burning-in and testing logic, optical, and memory integrated circuits... Show more
Aehr Test Systems designs and sells wafer-level and package-level test and burn-in systems that help semiconductor manufacturers screen out defective chips before they reach critical applications. Its core strategic shift has been to move beyond a historically concentrated EV silicon carbide business toward high-growth AI and data-center markets. Where more than 95% of revenue was once tied to SiC for electric vehicles, nearly 95% of fiscal 2026 revenue now comes from outside that segment.
The company's FOX-P wafer-level burn-in platforms and its newer Sonoma package-level solutions for AI accelerators, GPUs (graphics processing units), and high-performance computing processors position it as a turnkey reliability-testing provider from engineering through high-volume production. A recurring revenue element also matters: WaferPak contactors and burn-in boards are expected to remain around 30% of revenue, adding a consumables-like component to an otherwise lumpy capital-equipment model.
Structurally, Aehr competes against larger, well-capitalized players such as Teradyne and FormFactor. Its medium-term positioning depends on whether it can convert benchmark wins into high-volume production orders, particularly from a second major AI processor customer, while defending its intellectual property amid ongoing patent litigation against a Chinese competitor.
Several catalysts could shape investor sentiment over the coming quarters. First, the company's fiscal 2027 guidance of $130 million to $150 million in revenue — well above earlier consensus — remains the central benchmark investors will track. Management has signaled that the second fiscal quarter should be especially strong, driven by package-level Sonoma shipments.
Second, customer expansion is a key swing factor. Aehr completed a benchmark with a major supplier of AI accelerators, CPUs, and network processors and is moving toward pilot production validation in Taiwan, with little of that potential embedded in current guidance. A follow-on $22 million order for AI processor wafer-level burn-in systems and additional silicon photonics production orders underscore the pipeline.
Third, analyst activity has turned notably more constructive. Oppenheimer initiated coverage with an Outperform rating and a $120 price target in September 2026, while Jefferies launched coverage with a Buy and a $175 target. Craig-Hallum reiterated at $125, and Freedom Capital Markets upgraded the stock to Buy with a $110 target. The S&P Global consensus now stands at "Strong Buy," with an average price target near $128 — a meaningful upward revision from earlier in the year.
Finally, expansion into memory — including NAND and high-bandwidth memory (HBM) — remains a longer-dated but potentially large opportunity not assumed in the current guide.
Aehr's trajectory is closely tied to the artificial intelligence capital-expenditure cycle. As rising power consumption and package complexity increase the cost of late-stage chip failures, demand for burn-in screening intensifies — a structural tailwind for the company's equipment.
Interest rates and inflation remain indirect but relevant forces. Because Aehr sells capital equipment, higher financing costs could temper customer capital budgets, even as AI data-center investment remains resilient. Geopolitical factors also cut both ways: the U.S.-China technology environment supports domestic supply-chain diversification but adds litigation and export-control complexity, while the recovery of Chinese EV production benefits the company's silicon carbide franchise.
Technology adoption trends are the dominant driver. The proliferation of AI accelerators, silicon photonics for data-center interconnects, and next-generation power semiconductors (including gallium nitride and silicon MOSFETs) is broadening the testing-intensity curve that underpins Aehr's addressable market.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, ETF (exchange-traded fund), or other asset may trend bullish, bearish, or sideways over the coming week or month. It aims to surface developing trends, evaluate possible breakouts or reversals, and let users explore predictions across a broad range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. Traders monitoring Aehr Test Systems may find it a useful complement to fundamental analysis when gauging near-term price direction.
Looking toward 2026 and beyond, Aehr's story hinges on the durability of its AI-led ramp and its ability to broaden revenue concentration. Management has framed fiscal 2027 as the base for a multiyear growth setup rather than a one-quarter rebound, with non-GAAP pretax profitability targeted at 18% to 22% of revenue.
Several long-term themes merit close attention. Margin sustainability will depend on product mix, manufacturing utilization, and the recurring contribution from consumables. Technology transitions — including full wafer-level burn-in adoption for AI processors, silicon photonics expansion, and eventual memory qualification — could expand the earnings ceiling well beyond current assumptions. Capital allocation also matters: the company raised roughly $100 million in fiscal 2026, strengthening its balance sheet to fund capacity, research and development, and litigation.
Competitive threats from larger test-equipment incumbents, the pace of customer diversification, and regulatory or trade-policy shifts in China remain the principal watch items. Consensus analyst expectations have become markedly more optimistic, with an average price target near $128 — but sustaining that sentiment will require converting a record backlog and emerging benchmark wins into visible, repeated production revenue.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, AEHR has been closely correlated with TER. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if AEHR jumps, then TER could also see price increases.
| Ticker / NAME | Correlation To AEHR | 1D Price Change % | ||
|---|---|---|---|---|
| AEHR | 100% | -3.11% | ||
| TER - AEHR | 73% Closely correlated | -3.31% | ||
| ONTO - AEHR | 72% Closely correlated | -2.53% | ||
| FORM - AEHR | 71% Closely correlated | -1.15% | ||
| COHU - AEHR | 69% Closely correlated | -3.32% | ||
| LRCX - AEHR | 69% Closely correlated | -3.77% | ||
More | ||||
| Ticker / NAME | Correlation To AEHR | 1D Price Change % |
|---|---|---|
| AEHR | 100% | -3.11% |
| Electronic Production Equipment industry (30 stocks) | 78% Closely correlated | -0.08% |
| AEHR industry (14 stocks) | 77% Closely correlated | -4.22% |
a manufacturer of burn-in and test equipment for semiconductor manufacturing
Industry ElectronicProductionEquipment
The 50-day moving average for AEHR moved below the 200-day moving average on November 18, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AEHR as a result. In 73 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AEHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for AEHR entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AEHR's RSI Oscillator exited the oversold zone, 26 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for AEHR just turned positive on November 03, 2026. Looking at past instances where AEHR's MACD turned positive, the stock continued to rise in 33 of 38 cases over the following month. The odds of a continued upward trend are 87%.
Following a +21.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where AEHR advanced for three days, in 243 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.970) is normal, around the industry mean (5.670). AEHR has a moderately low P/E Ratio (-232.913) as compared to the industry average of (68.795). Projected Growth (PEG Ratio) (0.927) is also within normal values, averaging (0.801). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (51.813) is also within normal values, averaging (27.897).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. AEHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 77 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AEHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock better than average.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.